The aim of this study was to evaluate the efficacy of cimetropium bromide, a new antimuscarinic compound, in relieving symptoms of patients with irritable bowel syndrome over a three month period. Seventy consecutive outpatients were given cimetropium (50 mg tid) or placebo according to a double blind, randomised, parallel groups design. Symptoms were evaluated initially and at monthly intervals up to the end of the study period. One patient receiving placebo withdrew because of treatment failure. Pain score decreased by 40, 66,85% in the cimetropium group, at the end of the first, second and third months respectively, compared with 26, 32 and 52% reductions among controls (p=0 0005). At the end of treatment there was a 86% reduction in the number of abdominal pain episodes per day in the cimetropium group compared with 50% in the placebo group (p=0-001). Constipation and diarrhoea scores decreased by 59 and 49% in the cimetropium treated patients, compared with 37 and 39% in controls, the differences between being not significant. At the end of the study 89% of the patients treated with cimetropium considered themselves as globally improved as opposed to 69% in the placebo group (p=0 039). The corresponding 95% confidence intervals for the differences between the proportion of improved patients in the two groups were from 11% to 29%. Six patients taking cimetropium complained of slight dry mouth. The results of this study showed that cimetropium bromide is effective in relieving pain in patients with irritable bowel syndrome.
Despite its favourable prognosis, irritable bowel syndrome (IBS) is a social problem and up to 20% of the population are affected.' Half of the patients referred to gastroenterologists have irritable bowel syndrome. 2 Anticholinergics, antispasmodics, laxatives, and bulking agents, have all been used but no benefits have been clearly shown.34 Many studies, aimed at proving drug efficacy, have failed mainly because of the good response to placebo shown by these patients: placebo response rates were sometimes over 70%. [5] [6] [7] The placebo effects, however, tend to decrease with time8 so that the duration of the study treatment is crucial for a correct evaluation of the efficacy of any drug. Most studies were too short to produce good results. 9 A critical review of a large number of trials in irritable bowel syndrome was recently published'" concluding that not a single study of the many reviewed could offer convincing evidence in favour of the efficacy of any therapy tested in treating irritable bowel syndrome.
Cimetropium bromide is a new antispasmodic agent selectively acting on the gut by antagonising acetylcholine at the smooth muscle muscarinic receptors." 12 Unlike other antimuscarinics it has minimal effects on vascular receptors, so it has no appreciable untoward effects. '3 The aim of this study was to assess the efficacy of cimetropium bromide in improving the symptoms of irritable bowel syndrome over three months -a longer period than usual. of therapy. A similar trend was observed for severity of pain (26, 32 and 52% decreases). In cimetropium treated patients, severity and frequency of abdominal pain constantly decreased throughout the three months of treatment. Monthly decreases were 54, 73, and 86% for frequency and 40, 66, 85% for severity of abdominal pain. At the end of treatment, improvement of pain in the cimetropium group was significantly greater than in the placebo group both for frequency (p=0-001) and severity (p=00005).
Methods
At the end of treatment, severity of abdominal distension decreased by an average of 82% in the cimetropium group and 54% in the placebo group (p=0 055, Fig 3) .
Scores for severity of constipation and diarrhoea decreased by 59 and 49% in cimetropium treated patients and by 37 and 39% in placebo treated patients, the differences between treatment groups being not significant.
PHYSICAL EXAMINATION
At the pretreatment visit 54 (8)% of patients in the placebo group and 34 (8)% of patients in the cimetropium group complained ofpain on palpation. At the end of the study 17 (6)% of patients on placebo still presented pain on palpation while none of the patients given active drug complained of this (p=0-012, Fig 4) .
Evidence of contracted colon was found in 60 (8)% of patients in the cimetropium group at the beginning of the study and in 14 (6)% at the final visit, compared with 63 (8)% in the placebo group at the beginning, and 43 (8)% at the end (p=0-008, Fig 5) .
OVERALL ASSESSMENT OF THE TREATMENT
At the end of the study 89% of the patients treated with cimetropium considered themselves improved while only 69% of the placebo treated patients showed similar results, the difference between the two groups being significant (p= 0-039). The 95% confidence interval for the differences between the improvements in the two groups was 11 to 29%.
LABORATORY TESTS
Blood and urine tests were done before and at the end of treatment. No patient showed significant differences in laboratory values compared with initial results, in either the drug or the placebo group.
UNTOWARD EFFECTS
In the cimetropium group, six patients complained ofdry mouth. This effect is considered to be a typical anticholinergic manifestation of the OJ 2 3 Time (months) Figure 3 : Abdominal distension severityfor the placebo and the cimetropium groups during the three months oftreatment. 18 Although only 1 to 4% of the administered dose is absorbed,'9 the drug nevertheless reaches effective concentrations after repeated oral doses20 because of significant accumulation because of its long terminal half life (29 hours). When given intravenously at the dose of 5 and 10 mg, cimetropium bromide was effective in reducing the motor responses to a meal in the transverse and sigmoid colon of healthy subjects2' and in the sigmoid colon of patients with irritable bowel syndrome. 22 Six patients on cimetropium complained of dry mouth, a typical anticholinergic side effect. Patients taking anticholinergics who recognise side effects may come to recognise whether they are taking an active drug or placebo. This is a general problem in all placebo controlled trials with patients who are familiar with the possible side effects of the active drug.
In conclusion, the proper design and suitable duration ofthis study, together with the adequate size of the two groups investigated, confirms the results of previous smaller placebo controlled clinical trials2324 on the efficacy of cimetropium bromide in the treatment of irritable bowel syndrome.
